To amend title XXVII of the Public Health Service Act and title XIX of the Social Security Act to require coverage of Alzheimer's biomarker testing under group health plans, group and individual health insurance coverage, and the Medicaid program.

Jake Auchincloss

Democrat · MA · Representative

Source: Congress.gov · FEC

• Juan Ciscomani (R-AZ-6)Original· 2026-07-22

Referred to the House Committee on Energy and Commerce.

2026-07-22

Source: Congress.gov

Insurance companies and Medicaid would be required to cover blood tests that detect early signs of Alzheimer's disease, making these biomarker tests accessible to patients without out-of-pocket costs. This would apply to people covered by employer health plans, individual insurance policies, and Medicaid, potentially allowing doctors to identify Alzheimer's in its earliest stages before symptoms appear. The change aims to help more Americans get tested and potentially treated earlier, though the bill is still in the early stages of the legislative process.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

• HR6610Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
  Referred to Committee · 2026-07-22
• HR7568Hot Rock Act
  Referred to Committee · 2026-02-13
• HR6333Parents Over Platforms Act
  Referred to Committee · 2025-12-11
• HR6609Pharmacists Fight Back in Medicare and Medicaid Act
  Referred to Committee · 2025-12-11